Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
PlexusDx medical team reviews your complete medical history during the consultation process to identify these contraindications before prescribing
This finding is important
Survodutide Timeline Boehringer Ingelheims SYNCHRONIZE program includes multiple Phase 3 trials: SYNCHRONIZE-1: Obesity without type 2 diabetes (726 participants, 76 weeks) SYNCHRONIZE-2: Obesity with type 2 diabetes (755 participants, 76 weeks) SYNCHRONIZE-CVOT: Cardiovascular outcomes (4,935 participants target) LIVERAGE trials: MASH-specific studies initiated October 2024 FDA Breakthrough Therapy designation for MASH may accelerate review for that indication specifically
Available: [7] B
2023;35(45):e2304582
US$ 23.04
US$ 21.62
US$ 27.70
US$ 28.18
US$ 23.54
